Vaccine Info

TG4050 Cancer Vaccine

TG4050 Cancer Vaccine Description

TG4050 is individualized therapeutic vaccine designed to stimulate and educate the immune system of patients to recognize and destroy tumor cells. 

TG4050 has been designed to target up to 30 patient-specific neoantigens (cancer cell mutations) which are selected using NEC’s Neoantigen Prediction System, an advanced AI technology. The prediction system is based on more than 2 decades of expertise in AI and has been trained on proprietary immune data, allowing it to accurately prioritize and select the most immunogenic sequences.

Transgene uses its expertise in viral vectorization to incorporate the selected neoantigen sequences in the genome of the MVA viral vector. The Company has set up a unique in-house good manufacturing practice unit dedicated to manufacturing the individualized batches of TG4050 needed for the clinical development of this novel individualized therapeutic vaccine

The Company’s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac® platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO™ platform).

Transgene is a publicly-traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.

TG4050 Cancer Vaccine Indication

TG4050 is indicated for cancer patients who have already received first-line treatment. TG4050 is designed to target a panel of patient-specific mutations selected using NEC's Neoantigen Prediction System.

Therapeutic vaccines indirectly destroy diseased cells by causing a cascade of immune responses, which results in the production of "killer" T cells that specifically destroy tumor cells.

TG4050 Cancer Vaccine Dosage

TG4050 will be administered in the Phase 1 Clinical Trial as subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.

TG4050 Cancer Vaccine News

May 15, 2020 - Transgene and NEC announced that they will present data demonstrating that the prediction algorithm used to customize TG4050 for each patient is accurate at identifying immunogenic cancer mutations even among a large set of candidate mutations.

January 7, 2020 - Transgene and NEC start two clinical trials in oncology with TG4050, an individualized therapeutic vaccine thanks to artificial intelligence.

TG4050 Cancer Vaccine Clinical Trials 

Clinical Trial NCT03839524: A Trial Evaluating TG4050 in Ovarian Carcinoma

  • This is a multicenter, open-label, single-arm phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with ovarian, fallopian, or peritoneal serous carcinoma.
  • Estimated completion date: December 2021. Identifier: NCT04183166: A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

  • This is a multicenter, open-label, two arms, randomized, phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).
  • Estimated completion date: November 2021.